An Open-label, Randomized Study to Evaluate the Acute Immunologic Responses in Asian Subjects With E Antigen Positive Chronic Hepatitis B Following Initiation of Therapy for Hepatitis B With Pegasys, Nucleoside Analogues, or Both.
Phase of Trial: Phase I
Latest Information Update: 25 Jan 2016
At a glance
- Drugs Peginterferon alfa-2a (Primary) ; Tenofovir (Primary)
- Indications Hepatitis B
- Focus Therapeutic Use
- Sponsors Roche
- 01 Aug 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 06 Jul 2012 Actual patient number changed from 25 to 30 as reported by ClinicalTrials.gov.
- 06 Jul 2012 Planned end date changed from 1 Oct 2012 to 1 Sep 2012 as reported by ClinicalTrials.gov.